Organization & Developments: Provention Bio

Parents

2019: Provention Bio Is A Misunderstood Biotech With A Potential Quick Pathway To FDA Approval For Type 1 Diabetes Treatment_seekingalpha.com
2019: Provention Bio shares more than triple on diabetes prevention study results_www.cnbc.com
2019: Provention Bio: The Panacea For Diabetes_seekingalpha.com
2020: After midstage flop, Janssen says thanks but no thanks to Provention Bio drug
2020: Provention Bio: A Promising Small-Cap Immuno-Endocrinology Player For 2020_seekingalpha.com
2020: Provention: An Undercovered Healthcare Stock You Should Know About
2022: Provention Bio: Assessing The Investment Case After Teplizumab Approval_ seekingalpha.com
2022: Provention Bio: The Heat Is On Teplizumab For FDA Approval
A small-cap late-stage biotech company developing treatments for intercepting and preventing immune-mediated disease.
Provention is focused on the in-license, development, and commercialization of medicines to serve the unmet needs in autoimmune and inflammatory diseases.
Provention seeks to prevent and alter the disease course for conditions such as Diabetes Mellitus Type 1 (DM1 or Type 1 diabetes), Crohn's disease, celiac disease, lupus, and other life-threatening viral conditions.